Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
- Authors
- Ghia, Paolo; Pluta, Andrzej; Wach, Malgorzata; Lysak, Daniel; Kozak, Tomas; Simkovic, Martin; Kaplan, Polina; Kraychok, Iryna; Illes, Arpad; de la Serna, Javier; Dolan, Sean; Campbell, Philip; Musuraca, Gerardo; Jacob, Abe; Avery, E. J.; Lee, Jae Hoon; Liang, Wei; Patel, Priti; Quah, Cheng; Jurczak, Wojciech
- Issue Date
- Mar-2020
- Publisher
- TAYLOR & FRANCIS LTD
- Citation
- LEUKEMIA & LYMPHOMA, v.61, pp.235 - 237
- Journal Title
- LEUKEMIA & LYMPHOMA
- Volume
- 61
- Start Page
- 235
- End Page
- 237
- ISSN
- 1042-8194
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Lee, Jae Hoon
- College of Medicine (Department of Medicine)